デフォルト表紙
市場調査レポート
商品コード
1086983

経口ドラッグデリバリー:市場予測(2022年~2027年)

Oral Drug Delivery Market - Forecasts from 2022 to 2027

出版日: | 発行: Knowledge Sourcing Intelligence | ページ情報: 英文 111 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
経口ドラッグデリバリー:市場予測(2022年~2027年)
出版日: 2022年04月08日
発行: Knowledge Sourcing Intelligence
ページ情報: 英文 111 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の経口ドラッグデリバリーの市場規模は、2020年に983億200万米ドルとなり、予測期間中に6.04%のCAGRで推移し、2027年までには1,482億100万米ドルに達すると予測されています。

経口ドラッグデリバリーは非侵襲的であり、患者のコンプライアンス率が高く、取り扱いが容易で、特別な無菌状態を必要としないため、最も一般的な投与方法と考えられています。そのため、幅広い層の消費者に好まれています。また、予測期間中は、市場参加者間の協力関係の増加、慢性疾患の発生率の上昇、世界の高齢者人口の増加など、さまざまな要因が同市場を牽引すると予想されています。

当レポートでは、世界の経口ドラッグデリバリー市場を調査し、市場規模や予測、市場の促進要因および課題、市場動向、製剤別・用途別・地域別の市場分析、競合情勢、主要企業のプロファイルなどの体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション

第2章 調査手法

  • 調査データ
  • 前提条件

第3章 エグゼクティブサマリー

  • 調査のハイライト

第4章 市場力学

  • 市場促進要因
  • 市場抑制要因
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • バイヤーの交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • 業界のバリューチェーン分析

第5章 経口ドラッグデリバリー市場:製剤別

  • イントロダクション
  • 錠剤
  • カプセル
  • ドロップ
  • 粉末剤
  • 液体・シロップ
  • 煎じ薬

第6章 経口ドラッグデリバリー市場:用途別

  • イントロダクション
  • 病気の治療
  • 研究/学術目的

第7章 経口ドラッグデリバリー市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • その他
  • 中東・アフリカ
    • サウジアラビア
    • イスラエル
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • 韓国
    • インド
    • タイ
    • 韓国
    • 台湾
    • インドネシア
    • その他

第8章 競合環境と分析

  • 主要企業と戦略分析
  • 新興企業と市場の収益性
  • 合併、買収、合意、およびコラボレーション
  • ベンダー競争力マトリックス

第9章 企業プロファイル

  • Pfizer Inc.
  • AstraZeneca
  • Alpex Pharma S.A.
  • SPI Pharma
  • Globela Pharma Pvt Ltd
  • Lupin Pharmaceuticals, Inc.
  • Mayne Pharma Group Limited
  • Adare Pharmaceuticals, Inc.
  • AdhexPharma
  • Aquestive Therapeutics
目次
Product Code: KSI061612656

The oral drug delivery market is expected to grow at a CAGR of 6.04% during the forecast period to reach US$148.201 billion by 2027, from US$98.302 billion in 2020. Because oral drug delivery is noninvasive, has a high rate of patient compliance, is easy to handle, and does not require any special sterile conditions, it is considered the most popular method of administration. Hence, it is highly preferred by a wide spectrum of consumers. Because of the prevalence of chronic diseases around the world, these are in high demand. Moreover, rising research and development investment, advancing health expenditure, and an ageing population will all contribute to market expansion throughout the projection period. The oral drug delivery market can be segmented by formulation, application, and geography.

Various factors are expected to drive the oral drug delivery market during the forecast period, including an increase in the number of collaborations among market participants, an increase in the incidence of chronic diseases, and an increase in the global geriatric population.

People are embracing a more sedentary lifestyle as the middle class expands and urbanisation accelerates. Obesity rates and occurrences of diseases like diabetes are rising as a result of this. According to the World Health Organization, the prevalence of chronic disease will rise by 57% by 2020. GlobalData epidemiologists predict that by 2021, India will have 75.26 million diagnosed prevalent cases of type 2 diabetes and 26,000 diagnosed incident cases of endometrial cancer, with 91.72 million and 32,000 cases, respectively, by 2028. According to the American Cancer Society, in 2021, there will be 1.9 million new cancer diagnoses and 608,570 cancer deaths in the United States. According to a report published by Frontiers In Public Health, chronic noncommunicable diseases account for about 80% of the mortality among adults aged 60 in China, with ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and type 2 diabetes being the most common. Smoking, alcohol usage, sedentary activity, and poor nutritional intake are all significant contributors to these diseases. Oral drug delivery systems are expected to become more popular as the prevalence of chronic diseases rises around the world.

According to the World Population Prospects: the 2019 Revision, by 2050, one out of every six people on the planet will be over the age of 65 (16%), from one out of every eleven in 2019 (9%). One in every four people in Europe and North America could be 65 or older by 2050. In 2018, people aged 65 and older outnumbered kids under the age of five for the first time in history on a global level. From 143 million in 2019 to 426 million in 2050, the number of people aged 80 and up is expected to treble. Eastern and South-Eastern Asia's population aged 65 and above nearly doubled from 6% in 1990 to 11% in 2019, while Latin America and the Caribbean's population aged 65 and above nearly doubled from 5% in 1990 to 9% in 2019. The growing geriatric population around the world is also expected to propel market growth in the forecast period.

Moreover, rising research and development and partnerships amongst market players will expand the growth of oral delivery globally. For instance, SWK Holdings Corporation announced the acquisition of Enteris BioPharma in August 2019. This acquisition will allow the company to broaden its product line and provide more advanced products to its clients. This will also allow the company to become a pioneer in the field of orally delivered peptide and small molecule therapies. Similarly, in September 2021, Bio-Thera Solutions signed an agreement with Intract, acquiring the licence to employ the oral delivery system with a single monoclonal antibody that will remain unnamed. Moreover, in November 2021, EsoCap completed private funding round, with existing and new investors participating. The funds will be utilised to further develop and industrialise EsoCap's focused application technology, which will allow for the effective local therapy of esophageal illnesses.

During the projected period, North America is anticipated to dominate the oral drug delivery market.

During the forecast period, North America is expected to have a large market share. Technological advances, rising patent approvals, and research on the usage of nanotechnology for drug delivery in the region are expected to drive the market. For example, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical firm researching oral drug delivery systems, got a US patent in March 2019. Furthermore, due to the rapid adoption of new drug delivery technologies and the presence of research centres developing innovative drug delivery systems in the country, the United States is expected to hold a significant share of the oral drug delivery systems market in North America during the forecast period.

COVID -19 Insights

The COVID-19 pandemic has had a positive impact on the market for oral drug delivery because the demand for healthcare has increased exponentially around the world as a result of the virus outbreak. Since the disease's emergence, finding effective medications to treat COVID-19 has been a top priority. For instance, Merck and Ridgeback collaborated on the development of Molnupiravir, an oral antiviral medication. The drug delivery market has grown as a result of a lack of appropriate treatment, healthcare infrastructure, and medicine unavailability. Furthermore, as a result of the pandemic, the FDA clearance process became relatively easier, resulting in increased market growth.

Market Segmentation:

  • By Formulation

Tablets

Capsules

Drops

Powder

Liquid or Syrup

Decoction

  • By Application

Disease Treatment

Research/Academic purposes

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • Germany
  • France
  • United Kingdom
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • South Korea
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. ORAL DRUG DELIVERY MARKET, BY FORMULATION 

  • 5.1. Introduction
  • 5.2. Tablets
  • 5.3. Capsules
  • 5.4. Drops
  • 5.5. Powder
  • 5.6. Liquid or Syrup
  • 5.7. Decoction

6. ORAL DRUG DELIVERY MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Disease Treatment
  • 6.3. Research/Academic purposes

7. ORAL DRUG DELIVERY MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. South Korea
    • 7.6.4. India
    • 7.6.5. Thailand 
    • 7.6.6. South Korea
    • 7.6.7. Taiwan 
    • 7.6.8. Indonesia
    • 7.6.9. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisition, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Pfizer Inc.
  • 9.2. AstraZeneca
  • 9.3. Alpex Pharma S.A.
  • 9.4. SPI Pharma
  • 9.5. Globela Pharma Pvt Ltd
  • 9.6. Lupin Pharmaceuticals, Inc.
  • 9.7. Mayne Pharma Group Limited
  • 9.8. Adare Pharmaceuticals, Inc.
  • 9.9. AdhexPharma
  • 9.10. Aquestive Therapeutics